National Healthcare Safety Network Standardized Antimicrobial Administration Ratios (SAARs): A Progress Report and Risk Modeling Update Using 2017 Data. (26th March 2020)

• Record Type: Journal Article
• Authors: O'Leary, Erin N; Edwards, Jonathan R; Srinivasan, Arjun; Neuhauser, Melinda M; Webb, Amy K; Soe, Minn M; Hicks, Lauri A; Wise, Wendy; Wu, Hsiu; Pollock, Daniel A
• Is Part Of: Clinical infectious diseases. Volume 71:Number 10(2020)
• Page Start: e702
• Page End: e709
• Publication Date: 2020-03-26
• Subjects: antimicrobial use -- antibiotic stewardship -- hospital -- risk adjustment -- standardized metric; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa326
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: The Standardized Antimicrobial Administration Ratio (SAAR) is a risk-adjusted metric of antimicrobial use (AU) developed by the Centers for Disease Control and Prevention (CDC) in 2015 as a tool for hospital antimicrobial stewardship programs (ASPs) to track and compare AU with a national benchmark. In 2018, CDC updated the SAAR by expanding the locations and antimicrobial categories for which SAARs can be calculated and by modeling adult and pediatric locations separately. Methods: We identified eligible patient-care locations and defined SAAR antimicrobial categories. Predictive models were developed for eligible adult and pediatric patient-care locations using negative binomial regression applied to nationally aggregated AU data from locations reporting ≥9 months of 2017 data to the National Healthcare Safety Network (NHSN). Results: 2017 Baseline SAAR models were developed for 7 adult and 8 pediatric SAAR antimicrobial categories using data reported from 2156 adult and 170 pediatric locations across 457 hospitals. The inclusion of step-down units and general hematology-oncology units in adult 2017 baseline SAAR models and the addition of SAARs for narrow-spectrum B-lactam agents, antifungals predominantly used for invasive candidiasis, antibacterial agents posing the highest risk for Clostridioides difficile infection, and azithromycin (pediatrics only) expand the role SAARs can play in ASP efforts. Final risk-adjusted models are used to calculate predicted antimicrobial days, the denominator of the SAAR, for 40 SAAR types displayed in NHSN. Conclusions: SAARs can be used as a metric to prompt investigation into potential overuse or underuse of antimicrobials and to evaluate the effectiveness of ASP interventions. Abstract : This article describes 2017 baseline adult and pediatric Standardized Antimicrobial Administration Ratio predictive models, which were developed using antimicrobial use (AU) data submitted to the National Healthcare Safety Network AU Option from eligible patient-care locations in calendar year 2017.